



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bacopoulos et al. CONFIRMATION NUMBER: 6072
SERIAL NUMBER: 10/665,079 EXAMINER: Cybille Delacroix-Muirheid
FILING DATE: September 16, 2003 ART UNIT: 1614
FOR: METHODS OF TREATING CANCER WITH HDAC INHIBITORS

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Cited Reference B18;
4. Check Number 3855 in the amount of \$180.00; and
5. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24852-501 CIP5. Please address all correspondence to Customer Number 35437. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Dated: June 21, 2007

Michelle A. Iwamoto

Ivor Elrifi, Reg. No. 39,529
Michelle A. Iwamoto, Reg. No. 55,296
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS, *et al.*
666 Third Avenue, 24th Floor
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bacopoulos et al. CONFIRMATION NUMBER: 6072
SERIAL NUMBER: 10/665,079 EXAMINER: Cybille Delacroix-Muirheid
FILING DATE: September 16, 2003 ART UNIT: 1614
FOR: METHODS OF TREATING CANCER WITH HDAC INHIBITORS

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Cited Reference B18;
4. Check Number 3855 in the amount of \$180.00; and
5. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24852-501 CIP5. Please address all correspondence to Customer Number 35437. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Dated: June 21, 2007

EV942367373US

Michelle A. Iwamoto

Ivor Elrifi, Reg. No. 39,529

Michelle A. Iwamoto, Reg. No. 55,296

Attorneys for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS, *et al.*

666 Third Avenue, 24th Floor

New York, New York 10017


Phone: (212) 935-3000

Fax: (212) 983-3115

Express Mail Label No.: EV942367373US
Date of Deposit: June 21, 2007

Attorney Docket No.: 24852-501 CIP5

JUN 21 2007



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bacopoulos et al. CONFIRMATION NUMBER: 6072
SERIAL NUMBER: 10/665,079 EXAMINER: Cybille Delacroix-Muirheid
FILING DATE: September 16, 2003 ART UNIT: 1614
FOR: METHODS OF TREATING CANCER WITH HDAC INHIBITORS

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the document listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, a copy of which is submitted herewith.

This Supplemental Information Disclosure Statement is being filed more than three months after the filing date of this application but before mailing of any Final Action or Notice of Allowance under 37 C.F.R. §§1.113 or 1.311, respectively. Accordingly, the fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

06/25/2007 RIEBRAHT 00000043 10665079
180.00 US
01 FC:1806

Applicants: Bacopoulos *et al.*
U.S.S.N.: 10/665,079
Express Mail Label No.: EV942367373US
Date of Deposit: June 21, 2007

Attorney Docket No.: 24852-501 CIP5

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. **50-0311** Ref. No. **24852-501 CIP5**. Please address all correspondence to Customer Number **35437**.

Respectfully submitted,

Dated: June 21, 2007

Michelle A. Iwamoto

Ivor Elrifi, Reg. No. 39,529
Michelle A. Iwamoto, Reg. No. 55,296
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS, *et al.*
666 Third Avenue, 24th Floor
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115

Express Mail Label No.: EV942367373US
Date of Deposit: June 21, 2007

Attorney Docket No.: 24852-501 CIP5



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Bacopoulos et al. CONFIRMATION NUMBER: 6072
SERIAL NUMBER: 10/665,079 EXAMINER: Cybille Delacroix-Muirheid
FILING DATE: September 16, 2003 ART UNIT: 1614
FOR: METHODS OF TREATING CANCER WITH HDAC INHIBITORS

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the document listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, a copy of which is submitted herewith.

This Supplemental Information Disclosure Statement is being filed more than three months after the filing date of this application but before mailing of any Final Action or Notice of Allowance under 37 C.F.R. §§1.113 or 1.311, respectively. Accordingly, the fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Applicants: Bacopoulos *et al.*
U.S.S.N.: 10/665,079
Express Mail Label No.: EV942367373US
Date of Deposit: June 21, 2007

Attorney Docket No.: 24852-501 CIP5

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.


The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. **50-0311** Ref. No. **24852-501 CIP5**. Please address all correspondence to Customer Number **35437**.

Respectfully submitted,

Dated: June 21, 2007

Michelle A. Iwamoto

Ivor Elrifi, Reg. No. 39,529
Michelle A. Iwamoto, Reg. No. 55,296
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS, *et al.*
666 Third Avenue, 24th Floor
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115



/ Please type a plus sign (+) in this box

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO		Application Number	10/665,079
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	September 16, 2003
(use as many sheets as necessary)		First Named Inventor	Bacopoulos
		Group Art Unit / Confirmation No.	1614 / 6072
		Examiner Name	Cybille Delacroix-Muirheid
		Attorney Docket Number	24852-501 CIP5

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No
	B18	WO 05/023179	Aton Pharma, Inc.; Sloan-Kettering Institute for Cancer Research	March 17, 2005	X

NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail Label No.: EV942367373US
Date of Deposit: June 21, 2007

PAGE 1 of 1

/ Please type a plus sign (+) in this box

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO		Application Number	10/665,079
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	September 16, 2003
		First Named Inventor	Bacopoulos
		Group Art Unit / Confirmation No.	1614 / 6072
		Examiner Name	Cybille Delacroix-Muirheid
		Attorney Docket Number	24852-501 CIP5

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes	No
	B18	WO	05/023179	Aton Pharma, Inc.; Sloan-Kettering Institute for Cancer Research	March 17, 2005	X	

NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.